Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3B, Randomized Trail of Revlimid (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma

Next Previous
Trial Profile

Phase 3B, Randomized Trail of Revlimid (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ARUMM
  • Sponsors Celgene Corporation

Most Recent Events

  • 13 Apr 2021 Status changed from active, no longer recruiting to completed.
  • 05 Feb 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record. (Global end date:2020-10-12)
  • 27 Jan 2021 This trial has been completed in Greece, according to European Clinical Trials Database record. (Global end date:2020-10-12)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top